IGF-1 can help clinicians understand the growth hormone system, but it is not a stand-alone score of youth, vitality, or treatment success. Before or during Sermorelin treatment, its meaning depends on why the test was ordered, the person’s age and health, the laboratory method, and the decision the result is intended to guide.
A useful testing plan begins with a clinical question. Is the provider investigating possible hormone deficiency, monitoring an intervention, or evaluating an unexpected symptom? Those purposes can require different interpretation even when the laboratory report contains the same test name.
Understand the relationship between GH and IGF-1
Growth hormone, or GH, is released by the pituitary in pulses. Its concentration can vary substantially through the day. IGF-1 is influenced by growth hormone and is generally more stable in circulation, which makes it useful in assessment of this system.
The MedlinePlus IGF-1 test overview explains that relationship and the role of testing in growth hormone disorders. A more stable measurement is helpful, but it still does not capture every feature of secretion or tissue response.
Sermorelin stimulates GHRH signaling at the pituitary. A change in IGF-1 during treatment may be consistent with a hormonal response, but the clinician must interpret it alongside the circumstances and other findings.
Separate screening, diagnosis, and monitoring
A screening result can raise a question. A diagnosis requires evidence that fits the clinical condition. Monitoring follows a known problem or intervention over time. Confusing these roles can make a single result seem more conclusive than it is.
For example, a lower-than-expected IGF-1 may prompt further assessment, but it does not identify the cause on its own. A higher result during treatment may prompt review without proving that the desired symptom improved.
Ask the provider to state the purpose of the test before it is ordered. That answer makes the later conversation more focused and helps avoid treating every number outside a reference interval as a self-explanatory diagnosis.
Know why a random GH level can mislead
Because growth hormone secretion is pulsatile, a sample collected between pulses may show a low concentration even when the system can respond normally. A single random value therefore cannot be interpreted like a constant fuel gauge.
The MedlinePlus growth hormone testing guide describes stimulation and suppression testing, which examine how the system responds under controlled conditions. These tests address different questions and require clinical supervision.
Do not attempt to create a home stimulation test by changing sleep, food intake, exercise, or medicine use before a blood draw. Follow the ordering team’s preparation instructions and disclose anything that may have affected the planned conditions.
Distinguish normal aging from adult deficiency
IGF-1 and growth hormone patterns change across life. A lower value in an older adult than in a young adult is not, by itself, proof of a treatable deficiency.
The Endocrine Society adult deficiency guideline indicates that stimulation testing is usually required for confirmation, with defined exceptions. The likelihood of disease also depends on history and clinical findings, including whether there is a known pituitary problem.
Fatigue and reduced muscle mass are not specific enough to settle the diagnosis. The clinician may need to evaluate other explanations before attributing them to the growth hormone axis. The main Sermorelin article places these symptoms in context.
Read the reference interval with the result
A laboratory report should be interpreted using the reference information appropriate to that assay and patient. Age matters, and the report may present an age-adjusted interval or standardized score in addition to a concentration.
Do not compare a result with an online “optimal” target without understanding how that target was established. A range promoted for wellness is not automatically a validated threshold for better health or a reason to increase treatment.
If a report appears inconsistent with prior results, ask whether the same method and units were used. A numerical difference between laboratories may require interpretation before it is treated as a biological change.
Keep units and laboratory methods visible
Save the complete report, including the laboratory name, collection date, units, reference interval, and any interpretive comments. A number copied into a phone note can lose information that is essential to comparison.
For serial monitoring, ask whether using the same laboratory and method would improve comparability. The provider can decide how much weight to place on a change and whether repeat testing is appropriate.
Avoid converting or reformatting results without retaining the original. Even when a mathematical conversion is straightforward, the clinical interpretation may depend on more than the unit printed beside the value.
Discuss factors that can affect interpretation
The growth hormone–IGF system is influenced by broader health and physiology. Nutrition, illness, body composition, and other hormonal or medical conditions can matter. Medication history is also part of the assessment.
The Endotext review describes the multiple influences on this axis with aging. That complexity is one reason a single result should not be used to explain every symptom or define a universal treatment target.
Bring relevant diagnoses, recent illnesses, changes in weight or nutrition, and a complete medication list to the review. Do not stop a prescribed medicine to improve the appearance of a test result unless the treating team specifically instructs it.
Follow the actual preparation instructions
The ordering team should explain whether the planned blood draw requires any preparation and how its timing relates to the current treatment. Requirements may differ between a routine IGF-1 measurement and a dynamic hormone test.
Ask what to do if the preparation was not followed, an administration was missed, or an acute illness occurred. Report the event rather than quietly changing the schedule to make the record look consistent.
A clear record of actual use can help interpret monitoring. The Sermorelin label guide explains why the current prescription and concentration must remain unambiguous throughout the course.
Treat a higher IGF-1 as information, not a reward
A hormone increase may show that the pathway responded. It does not establish better sleep, greater strength, improved cognition, or longer healthy life. Those outcomes require their own assessment.
An unexpectedly high result also should not be celebrated as evidence that more treatment is better. The clinician needs to assess the level in context, review symptoms, and decide whether the plan needs to change.
Do not adjust the prescribed amount using a personal target or another patient’s result. The Sermorelin-versus-HGH comparison explains why even treatments acting in the same system cannot share a simple consumer dosing rule.
Pair laboratory monitoring with a functional question
If the goal involves body composition, identify what would count as a meaningful change in daily function or performance. If sleep is the concern, assess sleep itself. A laboratory result should complement, rather than replace, the original clinical question.
For example, someone might have an IGF-1 increase while their ability to complete ordinary activities remains unchanged. That is a mixed result requiring review, not proof that the intended benefit has occurred invisibly.
The body-composition article and sleep evidence article explain why those outcomes should be measured directly. Keeping the goal visible prevents monitoring from drifting into an endless effort to improve a number.
Make unexpected results reviewable
When a result is surprising, confirm the basic details first: patient, collection date, units, assay, reference interval, and treatment history. Ask whether the result fits the broader clinical picture and whether another test or evaluation is warranted.
Do not assume that every unexpected value is a laboratory error, but do not self-diagnose a tumor or hormone disorder from one report either. The appropriate next step depends on the result and the clinical circumstances.
New symptoms should be reported even if the most recent test was within its reference interval. A reassuring number cannot exclude every possible problem or substitute for assessment of an evolving concern.
Use a results-review worksheet
| Item | What to bring or ask |
|---|---|
| Purpose | What question was this test meant to answer? |
| Context | Age, relevant history, current treatment, and recent changes |
| Report | Full result, units, assay, reference interval, and collection date |
| Comparison | Whether prior results used comparable methods |
| Decision | What would this finding change about care? |
Keep copies of the interpretation as well as the raw reports. At a later appointment, knowing why a clinician made a decision can be more useful than a graph of values without context.
Decide when another test adds value
Repeat testing should have a reason: resolving uncertainty, monitoring a clinically relevant change, or checking a concern identified by the provider. More frequent measurements do not automatically produce better care.
Ask when the next review is appropriate and what should prompt contact sooner. The results-timeline guide connects laboratory monitoring with symptoms, function, and treatment burden.
A good testing plan turns data into a decision. It explains what the result can show, what remains uncertain, and how the next step serves the individual’s actual health goal.
Explore Sermorelin
CoreAge Rx offers provider-guided compounded Sermorelin. It acts on the growth hormone signaling pathway. Individual suitability, prescription directions, and follow-up need to be established with the treating clinician; historical GEREF approval does not mean this compounded product is FDA-approved. Review the current Sermorelin page and bring a complete medication and supplement list to the provider discussion.
Related reading
- Sermorelin: How It Works, Evidence, and Treatment Questions
- Sermorelin vs. HGH: Different Treatments and Different Evidence
- CoreAge Rx Sermorelin: A Product and Evidence Guide
- Creatine after 50 and strength training
Educational information; your prescription and clinician’s instructions guide individual care. Product details and linked sources checked September 15, 2026. Studies of another preparation or delivery route do not establish identical results for a finished compounded product. Photographs are illustrative and do not show treatment outcomes.
